You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
McKinsey
Johnson and Johnson
Boehringer Ingelheim
AstraZeneca

Last Updated: February 23, 2024

Capsaicin - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for capsaicin and what is the scope of freedom to operate?

Capsaicin is the generic ingredient in one branded drug marketed by Averitas and is included in one NDA. There are seven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Capsaicin has eighty-five patent family members in twenty-nine countries.

There are six drug master file entries for capsaicin. One supplier is listed for this compound.

Summary for capsaicin
Drug Prices for capsaicin

See drug prices for capsaicin

Drug Sales Revenue Trends for capsaicin

See drug sales revenues for capsaicin

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for capsaicin
Generic Entry Date for capsaicin*:
Constraining patent/regulatory exclusivity:
Dosage:
PATCH;TOPICAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for capsaicin

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Institute on Drug Abuse (NIDA)Early Phase 1
Duke UniversityEarly Phase 1
Chorda Pharma, Inc.Early Phase 1

See all capsaicin clinical trials

Medical Subject Heading (MeSH) Categories for capsaicin

US Patents and Regulatory Information for capsaicin

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Averitas QUTENZA capsaicin PATCH;TOPICAL 022395-001 Nov 16, 2009 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Averitas QUTENZA capsaicin PATCH;TOPICAL 022395-001 Nov 16, 2009 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Averitas QUTENZA capsaicin PATCH;TOPICAL 022395-001 Nov 16, 2009 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for capsaicin

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Averitas QUTENZA capsaicin PATCH;TOPICAL 022395-001 Nov 16, 2009 ⤷  Try a Trial ⤷  Try a Trial
Averitas QUTENZA capsaicin PATCH;TOPICAL 022395-001 Nov 16, 2009 ⤷  Try a Trial ⤷  Try a Trial
Averitas QUTENZA capsaicin PATCH;TOPICAL 022395-001 Nov 16, 2009 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for capsaicin

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Grunenthal GmbH Qutenza capsaicin EMEA/H/C/000909
Qutenza is indicated for the treatment of peripheral neuropathic pain in adults either alone or in combination with other medicinal products for pain.
Authorised no no no 2009-05-15
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
Harvard Business School
McKinsey
Mallinckrodt
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.